Overview

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate how BMS955176 affects pharmacokinetics (PK) of Dolutegravir (DTG) and also how DTG administration affects the PK of BMS955176

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb
ViiV Healthcare

Collaborator:

GlaxoSmithKline

Treatments:

BMS-955176
Dolutegravir